Direct and indirect costs and cost-driving factors of Tuberous sclerosis complex in children, adolescents, and caregivers: a multicenter cohort study.
Anti-seizure medication
Epilepsy
Everolimus
Rhabdomyoma
Seizure
mTOR inhibitor
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
21 06 2021
21 06 2021
Historique:
received:
21
11
2020
accepted:
29
05
2021
entrez:
22
6
2021
pubmed:
23
6
2021
medline:
30
6
2021
Statut:
epublish
Résumé
Tuberous sclerosis complex (TSC), a multisystem genetic disorder, affects many organs and systems, characterized by benign growths. This German multicenter study estimated the disease-specific costs and cost-driving factors associated with various organ manifestations in TSC patients. A validated, three-month, retrospective questionnaire was administered to assess the sociodemographic and clinical characteristics, organ manifestations, direct, indirect, out-of-pocket, and nursing care-level costs, completed by caregivers of patients with TSC throughout Germany. The caregivers of 184 patients (mean age 9.8 ± 5.3 years, range 0.7-21.8 years) submitted questionnaires. The reported TSC disease manifestations included epilepsy (92%), skin disorders (86%), structural brain disorders (83%), heart and circulatory system disorders (67%), kidney and urinary tract disorders (53%), and psychiatric disorders (51%). Genetic variations in TSC2 were reported in 46% of patients, whereas 14% were reported in TSC1. Mean total direct health care costs were EUR 4949 [95% confidence interval (95% CI) EUR 4088-5863, median EUR 2062] per patient over three months. Medication costs represented the largest direct cost category (54% of total direct costs, mean EUR 2658), with mechanistic target of rapamycin (mTOR) inhibitors representing the largest share (47%, EUR 2309). The cost of anti-seizure drugs (ASDs) accounted for a mean of only EUR 260 (5%). Inpatient costs (21%, EUR 1027) and ancillary therapy costs (8%, EUR 407) were also important direct cost components. The mean nursing care-level costs were EUR 1163 (95% CI EUR 1027-1314, median EUR 1635) over three months. Total indirect costs totaled a mean of EUR 2813 (95% CI EUR 2221-3394, median EUR 215) for mothers and EUR 372 (95% CI EUR 193-586, median EUR 0) for fathers. Multiple regression analyses revealed polytherapy with two or more ASDs and the use of mTOR inhibitors as independent cost-driving factors of total direct costs. Disability and psychiatric disease were independent cost-driving factors for total indirect costs as well as for nursing care-level costs. This study revealed substantial direct (including medication), nursing care-level, and indirect costs associated with TSC over three months, highlighting the spectrum of organ manifestations and their treatment needs in the German healthcare setting. DRKS, DRKS00016045. Registered 01 March 2019, http://www.drks.de/DRKS00016045.
Sections du résumé
BACKGROUND
Tuberous sclerosis complex (TSC), a multisystem genetic disorder, affects many organs and systems, characterized by benign growths. This German multicenter study estimated the disease-specific costs and cost-driving factors associated with various organ manifestations in TSC patients.
METHODS
A validated, three-month, retrospective questionnaire was administered to assess the sociodemographic and clinical characteristics, organ manifestations, direct, indirect, out-of-pocket, and nursing care-level costs, completed by caregivers of patients with TSC throughout Germany.
RESULTS
The caregivers of 184 patients (mean age 9.8 ± 5.3 years, range 0.7-21.8 years) submitted questionnaires. The reported TSC disease manifestations included epilepsy (92%), skin disorders (86%), structural brain disorders (83%), heart and circulatory system disorders (67%), kidney and urinary tract disorders (53%), and psychiatric disorders (51%). Genetic variations in TSC2 were reported in 46% of patients, whereas 14% were reported in TSC1. Mean total direct health care costs were EUR 4949 [95% confidence interval (95% CI) EUR 4088-5863, median EUR 2062] per patient over three months. Medication costs represented the largest direct cost category (54% of total direct costs, mean EUR 2658), with mechanistic target of rapamycin (mTOR) inhibitors representing the largest share (47%, EUR 2309). The cost of anti-seizure drugs (ASDs) accounted for a mean of only EUR 260 (5%). Inpatient costs (21%, EUR 1027) and ancillary therapy costs (8%, EUR 407) were also important direct cost components. The mean nursing care-level costs were EUR 1163 (95% CI EUR 1027-1314, median EUR 1635) over three months. Total indirect costs totaled a mean of EUR 2813 (95% CI EUR 2221-3394, median EUR 215) for mothers and EUR 372 (95% CI EUR 193-586, median EUR 0) for fathers. Multiple regression analyses revealed polytherapy with two or more ASDs and the use of mTOR inhibitors as independent cost-driving factors of total direct costs. Disability and psychiatric disease were independent cost-driving factors for total indirect costs as well as for nursing care-level costs.
CONCLUSIONS
This study revealed substantial direct (including medication), nursing care-level, and indirect costs associated with TSC over three months, highlighting the spectrum of organ manifestations and their treatment needs in the German healthcare setting.
TRIAL REGISTRATION
DRKS, DRKS00016045. Registered 01 March 2019, http://www.drks.de/DRKS00016045.
Identifiants
pubmed: 34154622
doi: 10.1186/s13023-021-01899-x
pii: 10.1186/s13023-021-01899-x
pmc: PMC8218507
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
282Références
Orphanet J Rare Dis. 2018 Jul 17;13(1):117
pubmed: 30016967
Curr Med Res Opin. 2011 Aug;27(8):1571-83
pubmed: 21692602
Front Neurol. 2018 Jun 15;9:414
pubmed: 29963000
J Med Econ. 2015;18(12):1060-70
pubmed: 26201433
Appl Health Econ Health Policy. 2019 Oct;17(5):707-722
pubmed: 31161366
Orphanet J Rare Dis. 2021 Jun 2;16(1):250
pubmed: 34078440
Epilepsia. 2015 Sep;56(9):1388-97
pubmed: 26235849
Value Health. 2008 Jul-Aug;11(4):539-44
pubmed: 18194408
Expert Rev Clin Pharmacol. 2021 Jun;14(6):749-760
pubmed: 33792454
Epilepsia. 2017 Apr;58(4):512-521
pubmed: 28276062
Orphanet J Rare Dis. 2020 Sep 25;15(1):264
pubmed: 32988393
Epilepsy Behav. 2020 Nov;112:107494
pubmed: 33181900
Nat Rev Dis Primers. 2016 May 26;2:16035
pubmed: 27226234
Orphanet J Rare Dis. 2020 Jan 21;15(1):23
pubmed: 31964424
Epilepsia. 2021 Mar;62(3):785-794
pubmed: 33534134
Seizure. 2019 Jul;69:92-98
pubmed: 31004927
BMJ Open. 2017 Oct 5;7(10):e015236
pubmed: 28982809
J Child Neurol. 2015 Apr;30(5):563-9
pubmed: 24667738
J Med Econ. 2018 Oct;21(10):953-959
pubmed: 29890870
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
Pediatr Neurol. 2013 Oct;49(4):243-54
pubmed: 24053982
Lancet Neurol. 2015 Jul;14(7):733-45
pubmed: 26067126
Pharmacoeconomics. 1998 May;13(5 Pt 1):487-97
pubmed: 10180748
Front Neurol. 2020 Aug 28;11:904
pubmed: 32982929
Genet Mol Biol. 2017 Jan-Mar;40(1):69-79
pubmed: 28222202
Epilepsia. 2017 Apr;58(4):522-530
pubmed: 28276060
Epilepsia. 2019 Aug;60(8):1697-1710
pubmed: 31247127
Epilepsy Behav. 2021 Feb;115:107647
pubmed: 33358132
J Med Econ. 2015 May;18(5):349-56
pubmed: 25525770
Pharmacoeconomics. 2008;26(6):463-76
pubmed: 18489198
World Neurosurg. 2016 Jul;91:97-105
pubmed: 27025453
Arch Neurol. 1991 Apr;48(4):400-1
pubmed: 2012513
J Med Econ. 2016 Dec;19(12):1116-1126
pubmed: 27310569
Eur J Hum Genet. 2005 Jun;13(6):731-41
pubmed: 15798777
J Med Econ. 2017 Apr;20(4):388-394
pubmed: 27998195
Chest. 2015 Aug;148(2):444-449
pubmed: 25789699
Gesundheitswesen. 2015 Jan;77(1):53-61
pubmed: 25025287
Ann Neurol. 2021 Feb;89(2):304-314
pubmed: 33180985
Neuroepidemiology. 2009;33(4):335-41
pubmed: 19887839
Lancet. 1998 May 16;351(9114):1490
pubmed: 9605811
Epilepsy Behav. 2012 Apr;23(4):451-7
pubmed: 22381385
Epilepsy Behav. 2018 Jun;83:28-35
pubmed: 29649671
Br J Dermatol. 2016 Jun;174(6):1282-9
pubmed: 26800857
Epilepsy Behav. 2019 Feb;91:94-98
pubmed: 29941212
Eur J Paediatr Neurol. 2019 May;23(3):392-403
pubmed: 30871879
J Med Econ. 2016 Nov;19(11):1087-1098
pubmed: 27267148